Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01891344 · ClinicalTrials.gov registry record · Phase 2

A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)

A Phase 2 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by pharmaand.

Completed
Registry status
Phase 2
Development phase
491
Enrollment target
20
Study locations

NCT01891344 is a Phase 2 study of Ovarian Cancer and Fallopian Tube Cancer that has completed, run by pharmaand. The registered enrollment target is 491 participants, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (32% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01891344, a Phase 2 study of Ovarian Cancer and Fallopian Tube Cancer, has completed, sponsored by pharmaand.

COMPLETED
Registry status
Phase 2
Development phase
491 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.

Conditions Studied

Ovarian Cancer Fallopian Tube Cancer Epithelial Ovarian Cancer Peritoneal Cancer

Interventions

  • DRUG Oral rucaparib

Study Locations (20)

California

  • Saint Jude Heritage Medical Center - Fullerton
  • University of California Los Angeles - Los Angeles
  • UC San Diego - San Diego
  • California Pacific Medical Center - San Francisco
  • University of California, San Francisco - San Francisco
  • Coastal Integrative Cancer Care - San Luis Obispo
  • Central Coast Medical Oncology - Santa Maria
  • Stanford University - Stanford

Florida

  • Mayo Clinic Jacksonville - Jacksonville
  • Altus Research - Lake Worth
  • University of Miami Hospital & Clinics Sylvester Comprehensive Cancer Center - Miami
  • Florida Hospital Cancer Institute - Orlando
  • UF Health Cancer Center - Orlando

Alaska

  • Providence Alaska Medical Center - Anchorage

Arizona

  • University of Arizona Cancer Center - Tucson

Colorado

  • Rocky Mountain Cancer Centers - Lakewood

Indiana

  • Horizon BioAdvance - Lafayette

Kentucky

  • Norton Cancer Institute - Louisville

Maryland

  • Johns Hopkins Kimmel Cancer Center - Baltimore

Trial Details

FieldValue
Enrollment Target 491 participants
Start Date 2013-10-30
Est. Completion 2021-09-28
Phase Phase 2

Sponsor

pharmaand

15 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01891344

The ClinicalTrials.gov registry entry for NCT01891344 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 491 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (32% lower). The listed sponsor is pharmaand, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Oral rucaparib is the first listed.

NCT01891344 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Alaska.

Frequently Asked Questions

What is clinical trial NCT01891344 about?

NCT01891344 is a clinical study titled "A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)". The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.

What is the current status of trial NCT01891344?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 491 participants. The study started on 2013-10-30. Estimated completion is 2021-09-28.

What conditions does trial NCT01891344 study?

This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Peritoneal Cancer.

What interventions are being tested in trial NCT01891344?

The interventions under investigation include: Oral rucaparib (DRUG).

Who is sponsoring clinical trial NCT01891344?

This trial is sponsored by pharmaand, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01891344 being conducted?

This trial has 20 study locations across Alaska, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ovarian Cancer

All registered trials for this condition

Fallopian Tube Cancer

All registered trials for this condition

Alaska

All trials with a study site in Alaska

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.